Head-to-head evidence
Dimethyl fumarate (Tecfidera) vs DRF
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Sclerosis
Shared mechanism: Nrf2 pathway (fumaric acid ester) · full Multiple Sclerosis pipeline
Dimethyl fumarate (Tecfidera)
Marketed by Biogen
NCT00451451 · Phase 3 · completed
This was a large (n=1417), randomized, double-blind, placebo-controlled Phase 3 trial with a hard clinical primary endpoint (annualized relapse rate, independently adjudicated). Both BG00012 dosing arms showed clearly separated confidence intervals from placebo on this primary endpoint (0.224 and 0.198 relapses/year vs 0.401 for placebo), indicating the drug met its primary comparison in the favorable direction, satisfying all the elements of well-designed, positive Phase 3 evidence.
Next expected readout: April 2028 · NCT07138833 (registry estimate)
DRF
Marketed by Biogen
NCT05083923 · Phase 3 · completed
The study was single-arm and open-label, with no randomization, blinding, or control group; 102 participants received treatment. Its posted primary outcomes were safety measures rather than a controlled clinical efficacy comparison, so there was no formal primary endpoint comparison to meet or miss.
Next expected readout: July 2034 · NCT07483632 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Dimethyl fumarate (Tecfidera)'s landscape · DRF's landscape